{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:44:13Z","timestamp":1789911853663,"version":"4.0.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL147108"],"award-info":[{"award-number":["R01HL147108"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL153350"],"award-info":[{"award-number":["R01HL153350"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL160992"],"award-info":[{"award-number":["R01HL160992"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL089598"],"award-info":[{"award-number":["R01HL089598"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["940595"],"award-info":[{"award-number":["940595"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12265-025-10716-w","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:41:07Z","timestamp":1761831667000},"page":"1525-1539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gene Therapy for Inherited Cardiac Arrhythmias"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3895-1585","authenticated-orcid":false,"given":"Mara R.","family":"Turkieltaub Paredes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0595-6661","authenticated-orcid":false,"given":"Mohit","family":"Hulsurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5044-672X","authenticated-orcid":false,"given":"Xander H. T.","family":"Wehrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"10716_CR1","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/0735-1097(92)90253-j","volume":"20","author":"P Brugada","year":"1992","unstructured":"Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20:1391\u20136. https:\/\/doi.org\/10.1016\/0735-1097(92)90253-j.","journal-title":"J Am Coll Cardiol."},{"issue":"5","key":"10716_CR2","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1161\/01.cir.91.5.1512","volume":"91","author":"A Leenhardt","year":"1995","unstructured":"Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 1995;91(5):1512\u20139. https:\/\/doi.org\/10.1161\/01.cir.91.5.1512.","journal-title":"Circulation"},{"key":"10716_CR3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/0092-8674(95)90359-3","volume":"80","author":"Q Wang","year":"1995","unstructured":"Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80:805\u201311. https:\/\/doi.org\/10.1016\/0092-8674(95)90359-3.","journal-title":"Cell"},{"key":"10716_CR4","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/s0735-1097(03)00465-0","volume":"41","author":"D Darbar","year":"2003","unstructured":"Darbar D, Herron KJ, Ballew JD, Jahangir A, Gersh BJ, Shen WK, et al. Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol. 2003;41:2185\u201392. https:\/\/doi.org\/10.1016\/s0735-1097(03)00465-0.","journal-title":"J Am Coll Cardiol"},{"key":"10716_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJM198801213180301","volume":"318","author":"G Thiene","year":"1988","unstructured":"Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988;318:129\u201333. https:\/\/doi.org\/10.1056\/NEJM198801213180301.","journal-title":"N Engl J Med"},{"key":"10716_CR6","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1161\/01.cir.102.8.921","volume":"102","author":"H Abriel","year":"2000","unstructured":"Abriel H, Wehrens XH, Benhorin J, Kerem B, Kass RS. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome. Circulation. 2000;102:921\u20135. https:\/\/doi.org\/10.1161\/01.cir.102.8.921.","journal-title":"Circulation"},{"key":"10716_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1126\/science.1094301","volume":"304","author":"XH Wehrens","year":"2004","unstructured":"Wehrens XH, Lehnart SE, Reiken SR, Deng SX, Vest JA, Cervantes D, et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science. 2004;304:292\u20136. https:\/\/doi.org\/10.1126\/science.1094301.","journal-title":"Science"},{"key":"10716_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nm.1942","volume":"15","author":"H Watanabe","year":"2009","unstructured":"Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380\u20133. https:\/\/doi.org\/10.1038\/nm.1942.","journal-title":"Nat Med"},{"key":"10716_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4672","author":"CE Dunbar","year":"2018","unstructured":"Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018. https:\/\/doi.org\/10.1126\/science.aan4672.","journal-title":"Science"},{"key":"10716_CR10","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","volume":"30","author":"A Pupo","year":"2022","unstructured":"Pupo A, Fernandez A, Low SH, Francois A, Suarez-Amaran L, Samulski RJ. AAV vectors: the Rubik\u2019s cube of human gene therapy. Mol Ther. 2022;30:3515\u201341. https:\/\/doi.org\/10.1016\/j.ymthe.2022.09.015.","journal-title":"Mol Ther"},{"key":"10716_CR11","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1161\/CIRCULATIONAHA.123.068111","volume":"150","author":"RH Bortolin","year":"2024","unstructured":"Bortolin RH, Nawar F, Park C, Trembley MA, Prondzynski M, Sweat ME, et al. Antisense oligonucleotide therapy for calmodulinopathy. Circulation. 2024;150:1199\u2013210. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.068111.","journal-title":"Circulation"},{"key":"10716_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1161\/CIRCRESAHA.111.263939","volume":"110","author":"M Denegri","year":"2012","unstructured":"Denegri M, Avelino-Cruz JE, Boncompagni S, De Simone SA, Auricchio A, Villani L, et al. Viral gene transfer rescues arrhythmogenic phenotype and ultrastructural abnormalities in adult calsequestrin-null mice with inherited arrhythmias. Circ Res. 2012;110:663\u20138. https:\/\/doi.org\/10.1161\/CIRCRESAHA.111.263939.","journal-title":"Circ Res"},{"key":"10716_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1161\/CIRCRESAHA.118.313369","volume":"123","author":"X Pan","year":"2018","unstructured":"Pan X, Philippen L, Lahiri SK, Lee C, Park SH, Word TA, et al. In vivo Ryr2 editing corrects catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2018;123:953\u201363. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313369.","journal-title":"Circ Res"},{"key":"10716_CR14","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.hrthm.2024.02.001","volume":"21","author":"J Mundisugih","year":"2024","unstructured":"Mundisugih J, Kumar S, Kizana E. Adeno-associated virus-mediated gene therapy for cardiac tachyarrhythmia: a systematic review and meta-analysis. Heart Rhythm. 2024;21:939\u201349. https:\/\/doi.org\/10.1016\/j.hrthm.2024.02.001.","journal-title":"Heart Rhythm"},{"key":"10716_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1161\/CIRCRESAHA.118.313406","volume":"123","author":"D Dobrev","year":"2018","unstructured":"Dobrev D, Wehrens XHT. Mouse models of cardiac arrhythmias. Circ Res. 2018;123:332\u20134. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313406.","journal-title":"Circ Res"},{"key":"10716_CR16","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nrcardio.2016.143","volume":"13","author":"J Sieira","year":"2016","unstructured":"Sieira J, Dendramis G, Brugada P. Pathogenesis and management of Brugada syndrome. Nat Rev Cardiol. 2016;13:744\u201356. https:\/\/doi.org\/10.1038\/nrcardio.2016.143.","journal-title":"Nat Rev Cardiol"},{"key":"10716_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1146\/annurev-med-042423-042903","volume":"76","author":"ER Dewars","year":"2025","unstructured":"Dewars ER, Landstrom AP. The genetic basis of sudden cardiac death: from diagnosis to emerging genetic therapies. Annu Rev Med. 2025;76:283\u201399. https:\/\/doi.org\/10.1146\/annurev-med-042423-042903.","journal-title":"Annu Rev Med"},{"key":"10716_CR18","doi-asserted-by":"publisher","first-page":"100468","DOI":"10.1016\/j.ijcha.2020.100468","volume":"26","author":"KHC Li","year":"2020","unstructured":"Li KHC, Lee S, Yin C, Liu T, Ngarmukos T, Conte G, et al. Brugada syndrome: a comprehensive review of pathophysiological mechanisms and risk stratification strategies. IJC Heart Vasc. 2020;26:100468. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100468.","journal-title":"IJC Heart Vasc"},{"key":"10716_CR19","doi-asserted-by":"publisher","first-page":"661413","DOI":"10.3389\/fphys.2021.661413","volume":"12","author":"N Doisne","year":"2021","unstructured":"Doisne N, Grauso M, Mougenot N, Clergue M, Souil C, Coulombe A, et al. In vivo dominant-negative effect of an SCN5A Brugada syndrome variant. Front Physiol. 2021;12:661413. https:\/\/doi.org\/10.3389\/fphys.2021.661413.","journal-title":"Front Physiol"},{"key":"10716_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf053","author":"J Wang","year":"2025","unstructured":"Wang J, Verkerk AO, Wilders R, Zhang Y, Zhang K, Prakosa A, et al. SCN10A-short gene therapy to restore conduction and protect against malignant cardiac arrhythmias. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf053.","journal-title":"Eur Heart J"},{"key":"10716_CR21","doi-asserted-by":"publisher","first-page":"eabf3136","DOI":"10.1126\/scitranslmed.abf3136","volume":"14","author":"G Yu","year":"2022","unstructured":"Yu G, Chakrabarti S, Tischenko M, Chen AL, Wang Z, Cho H, et al. Gene therapy targeting protein trafficking regulator MOG1 in mouse models of Brugada syndrome, arrhythmias, and mild cardiomyopathy. Sci Transl Med. 2022;14:eabf3136. https:\/\/doi.org\/10.1126\/scitranslmed.abf3136.","journal-title":"Sci Transl Med"},{"key":"10716_CR22","doi-asserted-by":"publisher","unstructured":"Gizon M FM, Fontaine V, Mougenot N, Laporte PL, Gaborit N, Extramiana F, Baro I, Guicheney P, Charpentier F, sne N, Neyroud N. Gene Therapy with the N-terminal Fragment of Nav1.5 for Cardiac Channelopathies: A Novel Transcomplementation Mechanism Potentiating the Cardiac Sodium Current. bioRvix. 2024:https:\/\/doi.org\/10.1101\/2024.10.30.621028.","DOI":"10.1101\/2024.10.30.621028"},{"key":"10716_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1161\/CIRCGENETICS.110.959130","volume":"4","author":"D Kattygnarath","year":"2011","unstructured":"Kattygnarath D, Maugenre S, Neyroud N, Balse E, Ichai C, Denjoy I, et al. MOG1: a new susceptibility gene for Brugada syndrome. Circ Cardiovasc Genet. 2011;4:261\u20138. https:\/\/doi.org\/10.1161\/CIRCGENETICS.110.959130.","journal-title":"Circ Cardiovasc Genet"},{"key":"10716_CR24","doi-asserted-by":"publisher","first-page":"6968","DOI":"10.1074\/jbc.M709721200","volume":"283","author":"L Wu","year":"2008","unstructured":"Wu L, Yong SL, Fan C, Ni Y, Yoo S, Zhang T, et al. Identification of a new co-factor, MOG1, required for the full function of cardiac sodium channel Nav 1.5. J Biol Chem. 2008;283:6968\u201378. https:\/\/doi.org\/10.1074\/jbc.M709721200.","journal-title":"J Biol Chem"},{"key":"10716_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1161\/CIRCEP.111.000206","volume":"6","author":"S Chakrabarti","year":"2013","unstructured":"Chakrabarti S, Wu X, Yang Z, Wu L, Yong SL, Zhang C, et al. MOG1 rescues defective trafficking of Na(v)1.5 mutations in Brugada syndrome and sick sinus syndrome. Circ Arrhythm Electrophysiol. 2013;6:392\u2013401. https:\/\/doi.org\/10.1161\/CIRCEP.111.000206.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10716_CR26","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1161\/01.cir.103.4.485","volume":"103","author":"PJ Laitinen","year":"2001","unstructured":"Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation. 2001;103:485\u201390. https:\/\/doi.org\/10.1161\/01.cir.103.4.485.","journal-title":"Circulation"},{"key":"10716_CR27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/bja\/57.2.234-a","volume":"57","author":"JW Dundee","year":"1985","unstructured":"Dundee JW, McMurray TJ. Infusion rates for I.V. anaesthesia. Br J Anaesth. 1985;57:234\u20135. https:\/\/doi.org\/10.1093\/bja\/57.2.234-a.","journal-title":"Br J Anaesth"},{"key":"10716_CR28","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/s0092-8674(03)00434-3","volume":"113","author":"XH Wehrens","year":"2003","unstructured":"Wehrens XH, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell. 2003;113:829\u201340. https:\/\/doi.org\/10.1016\/s0092-8674(03)00434-3.","journal-title":"Cell"},{"key":"10716_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1161\/CIRCRESAHA.117.310882","volume":"121","author":"R Bongianino","year":"2017","unstructured":"Bongianino R, Denegri M, Mazzanti A, Lodola F, Vollero A, Boncompagni S, et al. Allele-specific silencing of mutant mRNA rescues ultrastructural and arrhythmic phenotype in mice carriers of the R4496C mutation in the ryanodine receptor gene (RYR2). Circ Res. 2017;121:525\u201336. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.310882.","journal-title":"Circ Res"},{"key":"10716_CR30","doi-asserted-by":"publisher","unstructured":"Moore OM, Aguilar-Sanchez Y, Lahiri SK, Hulsurkar MM, Alberto Navarro-Garcia J, Word TA, et al. Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Aging. 2024;4. https:\/\/doi.org\/10.20517\/jca.2023.42.","DOI":"10.20517\/jca.2023.42"},{"key":"10716_CR31","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1161\/CIRCULATIONAHA.113.006901","volume":"129","author":"M Denegri","year":"2014","unstructured":"Denegri M, Bongianino R, Lodola F, Boncompagni S, De Giusti VC, Avelino-Cruz JE, et al. Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age. Circulation. 2014;129:2673\u201381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.006901.","journal-title":"Circulation"},{"key":"10716_CR32","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.hrthm.2017.03.025","volume":"14","author":"E Kurtzwald-Josefson","year":"2017","unstructured":"Kurtzwald-Josefson E, Yadin D, Harun-Khun S, Waldman M, Aravot D, Shainberg A, et al. Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models. Heart Rhythm. 2017;14:1053\u201360. https:\/\/doi.org\/10.1016\/j.hrthm.2017.03.025.","journal-title":"Heart Rhythm"},{"key":"10716_CR33","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.118.038514","volume":"140","author":"VJ Bezzerides","year":"2019","unstructured":"Bezzerides VJ, Caballero A, Wang S, Ai Y, Hylind RJ, Lu F, et al. Gene therapy for catecholaminergic polymorphic ventricular tachycardia by inhibition of Ca. Circulation. 2019;140:405\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038514.","journal-title":"Circulation"},{"key":"10716_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008155","author":"B Liu","year":"2018","unstructured":"Liu B, Walton SD, Ho HT, Belevych AE, Tikunova SB, Bonilla I, et al. Gene transfer of engineered calmodulin alleviates ventricular arrhythmias in a calsequestrin-associated mouse model of catecholaminergic polymorphic ventricular tachycardia. J Am Heart Assoc. 2018. https:\/\/doi.org\/10.1161\/JAHA.117.008155.","journal-title":"J Am Heart Assoc"},{"key":"10716_CR35","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.hrthm.2006.12.048","volume":"4","author":"C Napolitano","year":"2007","unstructured":"Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007;4:675\u20138. https:\/\/doi.org\/10.1016\/j.hrthm.2006.12.048.","journal-title":"Heart Rhythm"},{"key":"10716_CR36","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1161\/CIRCRESAHA.121.320661","volume":"131","author":"MJ Wleklinski","year":"2022","unstructured":"Wleklinski MJ, Kryshtal DO, Kim K, Parikh SS, Blackwell DJ, Marty I, et al. Impaired dynamic sarcoplasmic reticulum Ca buffering in autosomal dominant CPVT2. Circ Res. 2022;131:673\u201386. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.320661.","journal-title":"Circ Res"},{"key":"10716_CR37","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/j.jacc.2011.01.026","volume":"57","author":"C van der Werf","year":"2011","unstructured":"van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011;57:2244\u201354. https:\/\/doi.org\/10.1016\/j.jacc.2011.01.026.","journal-title":"J Am Coll Cardiol"},{"key":"10716_CR38","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1161\/01.RES.0000125626.33738.E2","volume":"94","author":"XH Wehrens","year":"2004","unstructured":"Wehrens XH, Lehnart SE, Reiken SR, Marks AR. Ca2+\/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res. 2004;94:e61. https:\/\/doi.org\/10.1161\/01.RES.0000125626.33738.E2.","journal-title":"Circ Res"},{"key":"10716_CR39","doi-asserted-by":"publisher","first-page":"12179","DOI":"10.1073\/pnas.0600268103","volume":"103","author":"PJ Kannankeril","year":"2006","unstructured":"Kannankeril PJ, Mitchell BM, Goonasekera SA, Chelu MG, Zhang W, Sood S, et al. Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc Natl Acad Sci U S A. 2006;103:12179\u201384. https:\/\/doi.org\/10.1073\/pnas.0600268103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10716_CR40","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1172\/jci37059","volume":"119","author":"MG Chelu","year":"2009","unstructured":"Chelu MG, Sarma S, Sood S, Wang S, van Oort RJ, Skapura DG, et al. Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin Invest. 2009;119:1940\u201351. https:\/\/doi.org\/10.1172\/jci37059.","journal-title":"J Clin Invest"},{"key":"10716_CR41","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.yjmcc.2010.10.001","volume":"50","author":"N Liu","year":"2011","unstructured":"Liu N, Ruan Y, Denegri M, Bachetti T, Li Y, Colombi B, et al. Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+\/-) mice with catecholaminergic polymorphic ventricular tachycardia. J Mol Cell Cardiol. 2011;50:214\u201322. https:\/\/doi.org\/10.1016\/j.yjmcc.2010.10.001.","journal-title":"J Mol Cell Cardiol"},{"key":"10716_CR42","doi-asserted-by":"publisher","first-page":"981","DOI":"10.7326\/0003-4819-137-12-200212170-00012","volume":"137","author":"XH Wehrens","year":"2002","unstructured":"Wehrens XH, Vos MA, Doevendans PA, Wellens HJ. Novel insights in the congenital long QT syndrome. Ann Intern Med. 2002;137:981\u201392. https:\/\/doi.org\/10.7326\/0003-4819-137-12-200212170-00012.","journal-title":"Ann Intern Med"},{"key":"10716_CR43","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.15252\/emmm.201404929","volume":"7","author":"Q Chang","year":"2015","unstructured":"Chang Q, Wang J, Li Q, Kim Y, Zhou B, Wang Y, et al. Virally mediated Kcnq1 gene replacement therapy in the immature scala media restores hearing in a mouse model of human Jervell and Lange-Nielsen deafness syndrome. EMBO Mol Med. 2015;7:1077\u201386. https:\/\/doi.org\/10.15252\/emmm.201404929.","journal-title":"EMBO Mol Med"},{"key":"10716_CR44","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1093\/eurheartj\/ehae476","volume":"45","author":"S Bains","year":"2024","unstructured":"Bains S, Giammarino L, Nimani S, Alerni N, Tester DJ, Kim CSJ, et al. KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome. Eur Heart J. 2024;45:3751\u201363. https:\/\/doi.org\/10.1093\/eurheartj\/ehae476.","journal-title":"Eur Heart J"},{"key":"10716_CR45","doi-asserted-by":"publisher","first-page":"101483","DOI":"10.1016\/j.scr.2019.101483","volume":"38","author":"Z Wang","year":"2019","unstructured":"Wang Z, Wang L, Liu W, Hu D, Gao Y, Ge Q, et al. Pathogenic mechanism and gene correction for LQTS-causing double mutations in KCNQ1 using a pluripotent stem cell model. Stem Cell Res. 2019;38:101483. https:\/\/doi.org\/10.1016\/j.scr.2019.101483.","journal-title":"Stem Cell Res"},{"key":"10716_CR46","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1161\/CIRCULATIONAHA.120.051836","volume":"143","author":"SM Dotzler","year":"2021","unstructured":"Dotzler SM, Kim CSJ, Gendron WAC, Zhou W, Ye D, Bos JM, et al. Suppression-replacement. Circulation. 2021;143:1411\u201325. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051836.","journal-title":"Circulation"},{"key":"10716_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1161\/CIRCULATIONAHA.123.065624","volume":"149","author":"M Qi","year":"2024","unstructured":"Qi M, Ma S, Liu J, Liu X, Wei J, Lu WJ, et al. In vivo base editing of Scn5a rescues type 3 long QT syndrome in mice. Circulation. 2024;149:317\u201329. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065624.","journal-title":"Circulation"},{"key":"10716_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/biom10081144","author":"M Ono","year":"2020","unstructured":"Ono M, Burgess DE, Schroder EA, Elayi CS, Anderson CL, January CT, et al. Long QT syndrome type 2: emerging strategies for correcting class 2 KCNH2 (hERG) mutations and identifying new patients. Biomolecules. 2020. https:\/\/doi.org\/10.3390\/biom10081144.","journal-title":"Biomolecules"},{"key":"10716_CR49","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1038\/emboj.2013.240","volume":"32","author":"M Bellin","year":"2013","unstructured":"Bellin M, Casini S, Davis RP, D\u2019Aniello C, Haas J, Ward-van Oostwaard D, et al. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J. 2013;32:3161\u201375. https:\/\/doi.org\/10.1038\/emboj.2013.240.","journal-title":"EMBO J"},{"key":"10716_CR50","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41467-020-20808-7","volume":"12","author":"X Wu","year":"2021","unstructured":"Wu X, Zhang L, Li Y, Zhang W, Wang J, Cai C, et al. Gene therapy via canalostomy approach preserves auditory and vestibular functions in a mouse model of Jervell and Lange-Nielsen syndrome type 2. Nat Commun. 2021;12:697. https:\/\/doi.org\/10.1038\/s41467-020-20808-7.","journal-title":"Nat Commun"},{"key":"10716_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/biom13010072","author":"MD McCoy","year":"2022","unstructured":"McCoy MD, Ullah A, Lederer WJ, Jafri MS. Understanding calmodulin variants affecting calcium-dependent inactivation of L-type calcium channels through whole-cell simulation of the cardiac ventricular myocyte. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom13010072.","journal-title":"Biomolecules"},{"key":"10716_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCRESAHA.120.316575","volume":"127","author":"C Roselli","year":"2020","unstructured":"Roselli C, Rienstra M, Ellinor PT. Genetics of atrial fibrillation in 2020: GWAS, genome sequencing, polygenic risk, and beyond. Circ Res. 2020;127:21\u201333. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.316575.","journal-title":"Circ Res"},{"key":"10716_CR53","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.fmre.2022.05.002","volume":"2","author":"H Hu","year":"2022","unstructured":"Hu H, Wang L, Li H, Li H, Chen X, Peng W, et al. Long-term amelioration of an early-onset familial atrial fibrillation model with AAV-mediated in vivo gene therapy. Fundam Res. 2022;2:829\u201335. https:\/\/doi.org\/10.1016\/j.fmre.2022.05.002.","journal-title":"Fundam Res"},{"key":"10716_CR54","doi-asserted-by":"publisher","first-page":"102606","DOI":"10.1016\/j.redox.2023.102606","volume":"60","author":"Y Zhong","year":"2023","unstructured":"Zhong Y, Tang K, Nattel S, Zhai M, Gong S, Yu Q, et al. Myosin light-chain 4 gene-transfer attenuates atrial fibrosis while correcting autophagic flux dysregulation. Redox Biol. 2023;60:102606. https:\/\/doi.org\/10.1016\/j.redox.2023.102606.","journal-title":"Redox Biol"},{"key":"10716_CR55","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/cvr\/cvaa239","volume":"117","author":"FS Rathjens","year":"2021","unstructured":"Rathjens FS, Blenkle A, Iyer LM, Renger A, Syeda F, Noack C, et al. Preclinical evidence for the therapeutic value of TBX5 normalization in arrhythmia control. Cardiovasc Res. 2021;117:1908\u201322. https:\/\/doi.org\/10.1093\/cvr\/cvaa239.","journal-title":"Cardiovasc Res"},{"key":"10716_CR56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/eurheartj\/ehw379","volume":"38","author":"DF Gudbjartsson","year":"2017","unstructured":"Gudbjartsson DF, Holm H, Sulem P, Masson G, Oddsson A, Magnusson OT, et al. A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation. Eur Heart J. 2017;38:27\u201334. https:\/\/doi.org\/10.1093\/eurheartj\/ehw379.","journal-title":"Eur Heart J"},{"key":"10716_CR57","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/cvr\/cvw003","volume":"109","author":"JF Ma","year":"2016","unstructured":"Ma JF, Yang F, Mahida SN, Zhao L, Chen X, Zhang ML, et al. TBX5 mutations contribute to early-onset atrial fibrillation in Chinese and Caucasians. Cardiovasc Res. 2016;109:442\u201350. https:\/\/doi.org\/10.1093\/cvr\/cvw003.","journal-title":"Cardiovasc Res"},{"key":"10716_CR58","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.118.035202","volume":"138","author":"C Yao","year":"2018","unstructured":"Yao C, Veleva T, Scott L Jr, Cao S, Li L, Chen G, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation. 2018;138:2227\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035202.","journal-title":"Circulation"},{"key":"10716_CR59","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.cell.2025.01.011","volume":"188","author":"VN Parikh","year":"2025","unstructured":"Parikh VN, Day SM, Lakdawala NK, Adler ED, Olivotto I, Seidman CE, et al. Advances in the study and treatment of genetic cardiomyopathies. Cell. 2025;188:901\u201318. https:\/\/doi.org\/10.1016\/j.cell.2025.01.011.","journal-title":"Cell"},{"key":"10716_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12061351","author":"J Mundisugih","year":"2024","unstructured":"Mundisugih J, Ravindran D, Kizana E. Exploring the therapeutic potential of gene therapy in Arrhythmogenic Right Ventricular Cardiomyopathy. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12061351.","journal-title":"Biomedicines"},{"key":"10716_CR61","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s44161-023-00370-3","volume":"2","author":"WH Bradford","year":"2023","unstructured":"Bradford WH, Zhang J, Gutierrez-Lara EJ, Liang Y, Do A, Wang TM, et al. Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics. Nat Cardiovasc Res. 2023;2:1246\u201361. https:\/\/doi.org\/10.1038\/s44161-023-00370-3.","journal-title":"Nat Cardiovasc Res"},{"key":"10716_CR62","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s44161-023-00378-9","volume":"2","author":"E Kyriakopoulou","year":"2023","unstructured":"Kyriakopoulou E, Versteeg D, de Ruiter H, Perini I, Seibertz F, Doring Y, et al. Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy. Nat Cardiovasc Res. 2023;2:1262\u201376. https:\/\/doi.org\/10.1038\/s44161-023-00378-9.","journal-title":"Nat Cardiovasc Res"},{"key":"10716_CR63","doi-asserted-by":"publisher","first-page":"e004305","DOI":"10.1161\/CIRCGEN.123.004305","volume":"17","author":"CJM van Opbergen","year":"2024","unstructured":"van Opbergen CJM, Narayanan B, Sacramento CB, Stiles KM, Mishra V, Frenk E, et al. AAV-mediated delivery of plakophilin-2a arrests progression of arrhythmogenic right ventricular cardiomyopathy in murine hearts: preclinical evidence supporting gene therapy in humans. Circ Genom Precis Med. 2024;17:e004305. https:\/\/doi.org\/10.1161\/CIRCGEN.123.004305.","journal-title":"Circ Genom Precis Med"},{"key":"10716_CR64","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1089\/hum.2008.123","volume":"19","author":"LT Bish","year":"2008","unstructured":"Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G, et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther. 2008;19:1359\u201368. https:\/\/doi.org\/10.1089\/hum.2008.123.","journal-title":"Hum Gene Ther"},{"key":"10716_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050785","author":"SS Issa","year":"2023","unstructured":"Issa SS, Shaimardanova AA, Solovyeva VV, Rizvanov AA. Various AAV serotypes and their applications in gene therapy: an overview. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12050785.","journal-title":"Cells"},{"key":"10716_CR66","doi-asserted-by":"publisher","first-page":"6602","DOI":"10.1038\/s41467-024-50555-y","volume":"15","author":"FE Eid","year":"2024","unstructured":"Eid FE, Chen AT, Chan KY, Huang Q, Zheng Q, Tobey IG, et al. Systematic multi-trait AAV capsid engineering for efficient gene delivery. Nat Commun. 2024;15:6602. https:\/\/doi.org\/10.1038\/s41467-024-50555-y.","journal-title":"Nat Commun"},{"key":"10716_CR67","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.omtm.2023.08.010","volume":"30","author":"CY Kok","year":"2023","unstructured":"Kok CY, Tsurusaki S, Cabanes-Creus M, Igoor S, Rao R, Skelton R, et al. Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes. Mol Ther. 2023;30:459\u201373. https:\/\/doi.org\/10.1016\/j.omtm.2023.08.010.","journal-title":"Mol Ther"},{"key":"10716_CR68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/d41573-021-00010-0","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A. Sarepta\u2019s DMD gene therapy falls flat. Nat Rev Drug Discov. 2021;20:91. https:\/\/doi.org\/10.1038\/d41573-021-00010-0.","journal-title":"Nat Rev Drug Discov"},{"key":"10716_CR69","doi-asserted-by":"publisher","first-page":"101147","DOI":"10.1016\/j.omtm.2023.101147","volume":"31","author":"J Shoti","year":"2023","unstructured":"Shoti J, Qing K, Keeler GD, Duan D, Byrne BJ, Srivastava A. Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy. Mol Ther Methods Clin Dev. 2023;31:101147. https:\/\/doi.org\/10.1016\/j.omtm.2023.101147.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10716_CR70","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41586-020-2890-8","volume":"587","author":"LM Moreira","year":"2020","unstructured":"Moreira LM, Takawale A, Hulsurkar M, Menassa DA, Antanaviciute A, Lahiri SK, et al. Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia. Nature. 2020;587:460\u20135. https:\/\/doi.org\/10.1038\/s41586-020-2890-8.","journal-title":"Nature"},{"key":"10716_CR71","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1161\/CIRCULATIONAHA.121.055373","volume":"144","author":"MM Hulsurkar","year":"2021","unstructured":"Hulsurkar MM, Lahiri SK, Moore O, Moreira LM, Abu-Taha I, Kamler M, et al. Atrial-specific LKB1 knockdown represents a novel mouse model of atrial cardiomyopathy with spontaneous atrial fibrillation. Circulation. 2021;144:909\u201312. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.055373.","journal-title":"Circulation"},{"key":"10716_CR72","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/jgm.1576","volume":"13","author":"KM Prasad","year":"2011","unstructured":"Prasad KM, Smith RS, Xu Y, French BA. A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction. J Gene Med. 2011;13:333\u201341. https:\/\/doi.org\/10.1002\/jgm.1576.","journal-title":"J Gene Med"},{"issue":"4","key":"10716_CR73","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1089\/hgtb.2012.105","volume":"23","author":"H Fang","year":"2012","unstructured":"Fang H, Lai NC, Gao MH, Miyanohara A, Roth DM, Tang T, et al. Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer. Hum Gene Ther Methods. 2012;23(4):234\u201341. https:\/\/doi.org\/10.1089\/hgtb.2012.105.","journal-title":"Hum Gene Ther Methods"},{"key":"10716_CR74","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/mt.2015.78","volume":"23","author":"G Moulay","year":"2015","unstructured":"Moulay G, Ohtani T, Ogut O, Guenzel A, Behfar A, Zakeri R, et al. Cardiac AAV9 gene delivery strategies in adult canines: assessment by long-term serial SPECT imaging of sodium iodide symporter expression. Mol Ther. 2015;23:1211\u201321. https:\/\/doi.org\/10.1038\/mt.2015.78.","journal-title":"Mol Ther"},{"key":"10716_CR75","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","volume":"29","author":"D Reichart","year":"2023","unstructured":"Reichart D, Newby GA, Wakimoto H, Lun M, Gorham JM, Curran JJ, et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat Med. 2023;29:412\u201321. https:\/\/doi.org\/10.1038\/s41591-022-02190-7.","journal-title":"Nat Med"},{"key":"10716_CR76","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","volume":"1","author":"RJ Samulski","year":"2014","unstructured":"Samulski RJ, Muzyczka N. AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol. 2014;1:427\u201351. https:\/\/doi.org\/10.1146\/annurev-virology-031413-085355.","journal-title":"Annu Rev Virol"},{"key":"10716_CR77","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41467-020-15272-2","volume":"11","author":"F Pinto","year":"2020","unstructured":"Pinto F, Thornton EL, Wang B. An expanded library of orthogonal split inteins enables modular multi-peptide assemblies. Nat Commun. 2020;11:1529. https:\/\/doi.org\/10.1038\/s41467-020-15272-2.","journal-title":"Nat Commun"},{"key":"10716_CR78","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2121-9-2","volume":"9","author":"AN Alexopoulou","year":"2008","unstructured":"Alexopoulou AN, Couchman JR, Whiteford JR. The CMV early enhancer\/chicken beta actin (CAG) promoter can be used to drive transgene expression during the differentiation of murine embryonic stem cells into vascular progenitors. BMC Cell Biol. 2008;9:2. https:\/\/doi.org\/10.1186\/1471-2121-9-2.","journal-title":"BMC Cell Biol"},{"key":"10716_CR79","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1161\/CIRCRESAHA.118.313811","volume":"124","author":"L Ni","year":"2019","unstructured":"Ni L, Scott L Jr., Campbell HM, Pan X, Alsina KM, Reynolds J, et al. Atrial-specific gene delivery using an adeno-associated viral vector. Circ Res. 2019;124:256\u201362. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313811.","journal-title":"Circ Res"},{"key":"10716_CR80","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1161\/CIRCULATIONAHA.120.052437","volume":"143","author":"AS Bilal","year":"2021","unstructured":"Bilal AS, Blackwood EA, Thuerauf DJ, Glembotski CC. Optimizing adeno-associated virus serotype 9 for studies of cardiac chamber-specific gene regulation. Circulation. 2021;143:2025\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052437.","journal-title":"Circulation"},{"key":"10716_CR81","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.yjmcc.2024.09.004","volume":"196","author":"W Mo","year":"2024","unstructured":"Mo W, Donahue JK. Gene therapy for atrial fibrillation. J Mol Cell Cardiol. 2024;196:84\u201393. https:\/\/doi.org\/10.1016\/j.yjmcc.2024.09.004.","journal-title":"J Mol Cell Cardiol"},{"key":"10716_CR82","doi-asserted-by":"publisher","first-page":"e012036","DOI":"10.1161\/CIRCEP.123.012036","volume":"17","author":"SK Hamrick","year":"2024","unstructured":"Hamrick SK, Kim CSJ, Tester DJ, Gencarelli M, Tobert KE, Gluscevic M, et al. Single Construct Suppression and Replacement Gene Therapy for the Treatment of All. Circ Arrhythm Electrophysiol. 2024;17:e012036. https:\/\/doi.org\/10.1161\/CIRCEP.123.012036.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10716_CR83","doi-asserted-by":"publisher","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13:975803. https:\/\/doi.org\/10.3389\/fimmu.2022.975803.","journal-title":"Front Immunol"},{"key":"10716_CR84","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365:2357\u201365. https:\/\/doi.org\/10.1056\/NEJMoa1108046.","journal-title":"N Engl J Med"},{"key":"10716_CR85","doi-asserted-by":"publisher","first-page":"497841","DOI":"10.1155\/2011\/497841","volume":"2011","author":"C Zaragoza","year":"2011","unstructured":"Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, et al. Animal models of cardiovascular diseases. J Biomed Biotechnol. 2011;2011:497841. https:\/\/doi.org\/10.1155\/2011\/497841.","journal-title":"J Biomed Biotechnol"},{"key":"10716_CR86","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/156652311796150372","volume":"11","author":"YS Ahi","year":"2011","unstructured":"Ahi YS, Bangari DS, Mittal SK. Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther. 2011;11:307\u201320. https:\/\/doi.org\/10.2174\/156652311796150372.","journal-title":"Curr Gene Ther"},{"key":"10716_CR87","doi-asserted-by":"publisher","first-page":"e003719","DOI":"10.1161\/CIRCGEN.122.003719","volume":"15","author":"S Bains","year":"2022","unstructured":"Bains S, Zhou W, Dotzler SM, Martinez K, Kim CJ, Tester DJ, et al. Suppression and replacement gene therapy for. Circ Genom Precis Med. 2022;15:e003719. https:\/\/doi.org\/10.1161\/CIRCGEN.122.003719.","journal-title":"Circ Genom Precis Med"},{"key":"10716_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071832","author":"M Wallen","year":"2023","unstructured":"Wallen M, Aqil F, Spencer W, Gupta RC. Exosomes as an emerging plasmid delivery vehicle for gene therapy. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15071832.","journal-title":"Pharmaceutics"},{"key":"10716_CR89","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jconrel.2024.04.018","volume":"369","author":"MCI Labonia","year":"2024","unstructured":"Labonia MCI, Estape Senti M, van der Kraak PH, Brans MAD, Dokter I, Streef TJ, et al. Cardiac delivery of modified mrna using lipid nanoparticles: cellular targets and biodistribution after intramyocardial administration. J Control Release. 2024;369:734\u201345. https:\/\/doi.org\/10.1016\/j.jconrel.2024.04.018.","journal-title":"J Control Release"},{"key":"10716_CR90","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385:493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454.","journal-title":"N Engl J Med"},{"key":"10716_CR91","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1159\/000485949","volume":"44","author":"Q Luo","year":"2017","unstructured":"Luo Q, Guo D, Liu G, Chen G, Hang M, Jin M. Exosomes from MiR-126-overexpressing adscs are therapeutic in relieving acute myocardial ischaemic injury. Cell Physiol Biochem. 2017;44:2105\u201316. https:\/\/doi.org\/10.1159\/000485949.","journal-title":"Cell Physiol Biochem"},{"key":"10716_CR92","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1002\/jcb.27731","volume":"120","author":"J Pan","year":"2019","unstructured":"Pan J, Alimujiang M, Chen Q, Shi H, Luo X. Exosomes derived from miR-146a-modified adipose-derived stem cells attenuate acute myocardial infarction-induced myocardial damage via downregulation of early growth response factor 1. J Cell Biochem. 2019;120:4433\u201343. https:\/\/doi.org\/10.1002\/jcb.27731.","journal-title":"J Cell Biochem"},{"key":"10716_CR93","doi-asserted-by":"publisher","first-page":"156914","DOI":"10.1016\/j.cyto.2025.156914","volume":"189","author":"T Kashkoulinejad Kouhi","year":"2025","unstructured":"Kashkoulinejad Kouhi T. Exosome-mediated communication between T cells and dendritic cells: implications for therapeutic strategies. Cytokine. 2025;189:156914. https:\/\/doi.org\/10.1016\/j.cyto.2025.156914.","journal-title":"Cytokine"},{"key":"10716_CR94","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-024-07310-6","volume":"628","author":"X Chen","year":"2024","unstructured":"Chen X, Birey F, Li MY, Revah O, Levy R, Thete MV, et al. Antisense oligonucleotide therapeutic approach for Timothy syndrome. Nature. 2024;628:818\u201325. https:\/\/doi.org\/10.1038\/s41586-024-07310-6.","journal-title":"Nature"},{"key":"10716_CR95","doi-asserted-by":"publisher","first-page":"753467","DOI":"10.3389\/fimmu.2021.753467","volume":"12","author":"K Rapti","year":"2021","unstructured":"Rapti K, Grimm D. Adeno-Associated viruses (AAV) and host immunity - a race between the hare and the hedgehog. Front Immunol. 2021;12:753467. https:\/\/doi.org\/10.3389\/fimmu.2021.753467.","journal-title":"Front Immunol"},{"key":"10716_CR96","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-pharmtox-022724-095035","volume":"65","author":"Z Yildirim","year":"2025","unstructured":"Yildirim Z, Swanson K, Wu X, Zou J, Wu J. Next-Gen therapeutics: pioneering drug discovery with iPSCs, genomics, AI, and clinical trials in a dish. Annu Rev Pharmacol Toxicol. 2025;65:71\u201390. https:\/\/doi.org\/10.1146\/annurev-pharmtox-022724-095035.","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10716-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-025-10716-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10716-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:19:28Z","timestamp":1765549168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-025-10716-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10716"],"URL":"https:\/\/doi.org\/10.1007\/s12265-025-10716-w","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"X.H.T.W. is a consultant and stock owner of Rocket Pharmaceuticals and has received research funding from this company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}